Although different translational approaches to FTI response prediction have been described, such as a two-gene classifier (RASGRP1/APTX) in patients with acute myeloid leukaemia (AML), there is still no reliable biomarker available for predicting the FTI response [18]. This evidence concerns the gene RASGRP1 and acute myeloid leukemia.